Boryung completes Phase 2 registration for Bosmorcibu, aims to file for approval in 2028
Predicted impact: Low
Phase 2 trial enrollment milestone; the enrollment completion was already reported in the last 14 days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.